Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Pollen Allergenic Extract [EPC]
Betula Occidentalis Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of type I hypersensitivity to Water Birch. It belongs to the class of Non-Standardized Pollen Allergenic Extracts.
Name
Betula Occidentalis Pollen
Raw Name
BETULA OCCIDENTALIS POLLEN
Category
Non-Standardized Pollen Allergenic Extract [EPC]
Drug Count
10
Variant Count
10
Last Verified
February 17, 2026
About Betula Occidentalis Pollen
Betula Occidentalis Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of type I hypersensitivity to Water Birch. It belongs to the class of Non-Standardized Pollen Allergenic Extracts.
Detailed information about Betula Occidentalis Pollen
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Betula Occidentalis Pollen.
Betula Occidentalis Pollen, commonly known as Water Birch pollen, is a biological substance used in clinical immunology for the diagnosis and treatment of allergic diseases. It belongs to a class of drugs known as Non-Standardized Pollen Allergenic Extracts [EPC]. These extracts are derived from the male catkins of the Betula occidentalis tree, a species native to western North America. In the context of clinical pharmacology, this substance is categorized as an allergen—a substance capable of inducing a specific immune response in sensitized individuals.
The primary clinical application of Betula Occidentalis Pollen extract is twofold: first, as a diagnostic tool in skin testing (percutaneous or intradermal) to identify patients with allergic rhinitis (hay fever) or allergic asthma triggered by birch pollen; and second, as an active ingredient in allergen immunotherapy (AIT), often referred to as 'allergy shots.' The goal of immunotherapy is to induce immunological tolerance, thereby reducing the severity of symptoms upon subsequent natural exposure to the pollen.
According to the FDA-approved labeling for allergenic extracts, these products have been used for decades under the 'grandfather' clauses of the Federal Food, Drug, and Cosmetic Act, though modern preparations are manufactured under strict Current Good Manufacturing Practices (cGMP). It is important to note that as a 'non-standardized' extract, its potency is typically measured in Protein Nitrogen Units (PNU) or Weight/Volume (w/v) ratios rather than bioequivalent allergy units (BAU), which are reserved for standardized extracts like those for short ragweed or certain grasses.
To understand how Betula Occidentalis Pollen works, one must first understand the pathophysiology of a Type I hypersensitivity reaction. In an allergic individual, the first exposure to Water Birch pollen leads to the production of allergen-specific Immunoglobulin E (IgE) antibodies. These antibodies bind to high-affinity receptors on the surface of mast cells and basophils. When the patient is re-exposed to the pollen, the allergen cross-links the IgE on these cells, triggering the release of inflammatory mediators like histamine, leukotrienes, and cytokines. This results in the classic symptoms of sneezing, itching, rhinorrhea (runny nose), and bronchial constriction.
When used in immunotherapy, Betula Occidentalis Pollen works by modulating the immune system's response. By administering gradually increasing doses of the allergen, the body undergoes several key immunological shifts:
Over time, this process leads to desensitization, where the patient can tolerate higher levels of natural pollen exposure without experiencing significant clinical symptoms.
Traditional pharmacokinetic studies (Absorption, Distribution, Metabolism, and Elimination) are not typically performed for allergenic extracts because they are complex mixtures of proteins and glycoproteins rather than single chemical entities. However, the following principles apply to their clinical use:
Betula Occidentalis Pollen is indicated for the following:
Betula Occidentalis Pollen is available in several concentrated forms for clinical use:
> Important: Only your healthcare provider can determine if Betula Occidentalis Pollen is right for your specific condition. The administration of this extract must always be performed by a trained medical professional in a facility equipped to treat anaphylaxis.
The dosage of Betula Occidentalis Pollen is highly individualized and must be determined by an allergist based on the patient's sensitivity level and clinical history. There is no 'standard' dose for all patients.
Immunotherapy consists of two distinct phases:
Betula Occidentalis Pollen is used in children, but the dosage must be approached with extreme caution. Children are generally started at the same dilutions as adults, but the volume of the injection may be adjusted based on the child's size and the physician's assessment of their reactive threshold. Studies have shown that immunotherapy is effective in children as young as 5 years old for the prevention of new sensitizations and the progression of rhinitis to asthma.
No specific dosage adjustments are required for patients with renal impairment, as the proteins are metabolized proteolytically. However, the patient's overall health and ability to tolerate a systemic reaction must be considered.
No dosage adjustments are necessary for hepatic impairment.
Elderly patients may be at higher risk for complications if a systemic reaction occurs, particularly if they have underlying cardiovascular disease. Dosing should be conservative, and the benefit-risk ratio must be carefully evaluated.
Betula Occidentalis Pollen extract is never self-administered. It must be given via subcutaneous injection (for immunotherapy) or via skin application (for testing) in a medical office.
If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on how much time has passed. If a dose is missed during the maintenance phase by more than 1-2 weeks, the allergist will typically reduce the dose for the next injection to ensure safety.
An 'overdose' in the context of allergenic extracts refers to receiving a dose higher than the patient's current tolerance level. This can lead to a severe systemic reaction or anaphylaxis.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Always inform your doctor if you are feeling unwell on the day of your scheduled injection.
Most patients undergoing treatment with Betula Occidentalis Pollen will experience local reactions. These are generally not dangerous but can be uncomfortable.
> Warning: Stop taking Betula Occidentalis Pollen and call your doctor immediately if you experience any of these symptoms of anaphylaxis.
There are no known long-term 'toxic' effects of Betula Occidentalis Pollen extract, as it is a natural protein. However, the long-term benefit is the potential 'cure' of the allergy. In rare cases, prolonged immunotherapy has been associated with the development of serum sickness or vasculitis, though these are extremely uncommon in modern practice.
While not all non-standardized extracts carry a formal 'Black Box Warning' in the same way as some pharmaceutical drugs, the FDA-approved class labeling for all allergenic extracts includes a prominent warning regarding Anaphylaxis.
Summary of Warning: This product can cause severe, life-threatening systemic reactions, including anaphylaxis. It should only be administered by physicians who are exceptionally experienced in the treatment of allergic diseases and the management of emergencies. Patients with unstable asthma are at a higher risk for fatal reactions. Epinephrine must be immediately available at the time of administration.
Report any unusual symptoms to your healthcare provider. Even a large local reaction should be reported, as it may be a precursor to a systemic reaction at the next, higher dose.
Betula Occidentalis Pollen extract is a potent biological agent. Its use is restricted to diagnostic and therapeutic purposes under the supervision of a specialist. The most critical safety consideration is the risk of a systemic allergic reaction. Patients must be stable and relatively symptom-free before receiving an injection. For example, if a patient is experiencing an acute asthma flare-up, the immunotherapy injection should be postponed.
No specific 'Black Box' exists for the Water Birch name specifically, but the Allergenic Extract Class Warning is mandatory. It states that these products may cause severe systemic reactions. Injections should never be given in a setting where emergency resuscitation equipment and trained personnel are not immediately available.
No routine lab tests (like blood counts or liver enzymes) are required for patients on Betula Occidentalis Pollen. However, clinical monitoring is intensive:
Generally, Betula Occidentalis Pollen does not affect the ability to drive. However, if a patient experiences a systemic reaction or receives antihistamines/epinephrine for a reaction, they should not drive until they are fully recovered and cleared by a physician.
There is no direct chemical interaction between alcohol and Betula Occidentalis Pollen. However, alcohol consumption can cause vasodilation (widening of blood vessels), which might theoretically increase the rate of allergen absorption or mask the early signs of an allergic reaction. It is generally advised to avoid alcohol for several hours before and after an injection.
Immunotherapy can be discontinued at any time, but the benefits of desensitization will be lost if the course is not completed (usually 3-5 years). There is no 'withdrawal syndrome' associated with stopping allergenic extracts.
> Important: Discuss all your medical conditions with your healthcare provider before starting Betula Occidentalis Pollen. Ensure they know about any history of fainting, heart problems, or severe asthma.
There are no specific food interactions with Betula Occidentalis Pollen extract itself. However, patients with birch pollen allergy often suffer from Oral Allergy Syndrome (OAS). This is a cross-reaction where the immune system recognizes similar proteins in certain fruits and vegetables (such as apples, peaches, carrots, and hazelnuts). While immunotherapy for birch pollen may sometimes improve OAS symptoms, it is not a primary treatment for food allergies.
There are no well-documented interactions between herbal supplements and allergenic extracts. However, supplements that have immune-modulating effects (like Echinacea or high-dose Astragalus) should be discussed with an allergist, as they could theoretically interfere with the desensitization process.
Betula Occidentalis Pollen will affect the results of specific allergy tests:
For each major interaction, the mechanism is usually pharmacodynamic—meaning the drugs affect how the body responds to the allergen or the emergency medications used to treat a reaction. The management strategy is typically to switch the patient to an alternative medication (e.g., switching from a beta-blocker to a calcium channel blocker) before starting immunotherapy.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any medications for blood pressure or heart rhythm.
Betula Occidentalis Pollen shows significant cross-reactivity with other members of the Betulaceae family. This includes:
Patients allergic to Water Birch are almost certainly allergic to these other species. This cross-reactivity is due to highly conserved proteins, most notably the 'Bet v 1' allergen family. Healthcare providers must consider this when designing an immunotherapy mix to avoid 'double-dosing' the patient with cross-reactive proteins.
> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and current medications, before prescribing Betula Occidentalis Pollen.
Betula Occidentalis Pollen is categorized as Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether it can cause fetal harm.
There is no evidence that allergenic extract proteins pass into breast milk in any significant quantity. Furthermore, even if they did, they would likely be digested in the infant's stomach. Immunotherapy is generally considered safe for breastfeeding mothers. The primary concern remains the mother's safety and the management of any potential systemic reactions.
Immunotherapy with Betula Occidentalis Pollen is approved for use in children. Clinical trials and observational studies have shown it to be effective in reducing symptoms of allergic rhinitis and potentially preventing the development of asthma (the 'Allergic March').
Patients over age 65 can receive Betula Occidentalis Pollen, but they require a thorough cardiovascular evaluation first. The elderly are more likely to be on medications like beta-blockers or ACE inhibitors and are less likely to tolerate the hemodynamic stress of anaphylaxis. Dosing should be cautious, and the maintenance dose may be lower than that used in younger adults.
Renal impairment does not significantly affect the use of allergenic extracts. No specific GFR-based adjustments are published in the clinical literature. The focus should remain on the patient's general stability.
There are no known issues with using Betula Occidentalis Pollen in patients with liver disease. The proteins are not metabolized by the cytochrome P450 system in the liver.
> Important: Special populations require individualized medical assessment. Always inform your allergist if you become pregnant or develop new health problems during the course of your treatment.
Betula Occidentalis Pollen extract works through 'Allergen-Specific Immunotherapy' (ASIT). At the molecular level, the extract contains various proteins, the most significant being the Bet v 1 homolog. When injected subcutaneously, these proteins are taken up by peripheral dendritic cells. These cells process the allergens and present them to naive T-cells in the lymph nodes.
In an allergic person, this presentation normally favors the development of Th2 cells. However, the repeated, escalating doses in immunotherapy favor the development of Regulatory T-cells (Tregs). These Tregs produce IL-10 and TGF-beta, which suppress the allergic cascade. Furthermore, B-cells are signaled to switch production from IgE to IgG4. IgG4 acts as a 'decoy' or 'blocking antibody,' binding to the birch pollen proteins before they can reach the IgE on mast cells, thus preventing the release of histamine.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous/Local) |
| Protein Binding | Primarily to IgG4 and IgE |
| Half-life | Days (for the immunological signal) |
| Tmax | 1-2 hours (for systemic absorption of proteins) |
| Metabolism | Proteolysis by tissue macrophages |
| Excretion | Renal (as small peptide fragments) |
Betula Occidentalis Pollen extract is a complex biological mixture. It is not a single chemical formula. It contains:
This product is classified as a Non-Standardized Pollen Allergenic Extract. It is related to other tree pollen extracts such as Oak, Maple, and Juniper. Unlike 'Standardized' extracts, the potency of Water Birch is determined by the manufacturer based on internal reference standards rather than a universal FDA bioequivalent unit.
Common questions about Betula Occidentalis Pollen
Betula Occidentalis Pollen extract is primarily used for the diagnosis and treatment of seasonal allergies caused by the Water Birch tree. In diagnostic settings, it is applied to the skin to see if a patient develops a 'wheal and flare' reaction, confirming an allergy. In therapeutic settings, it is used in 'allergy shots' (immunotherapy) to desensitize the immune system over time. This treatment helps reduce symptoms like sneezing, itchy eyes, and asthma that occur during the spring when birch trees release their pollen. It is intended for patients who do not get enough relief from standard allergy medications.
The most common side effects are local reactions at the site of the injection or skin test. These include redness, swelling, and itching that usually appear within minutes and fade within a few hours. Some patients may also experience 'late-phase' swelling that appears several hours later and can involve a larger area of the arm. Systemic symptoms like mild tiredness or a temporary increase in hay fever symptoms can also occur. While rare, severe reactions like hives or difficulty breathing are possible and require immediate medical attention.
While there is no direct chemical interaction between alcohol and the pollen extract, it is generally recommended to avoid alcohol on the day of your immunotherapy injection. Alcohol can cause your blood vessels to dilate, which might speed up the absorption of the allergen into your bloodstream, potentially increasing the risk of a reaction. Additionally, being under the influence of alcohol can make it harder for you to notice the early, subtle signs of a serious allergic reaction. Always follow the specific lifestyle advice provided by your allergist regarding your treatment days.
Betula Occidentalis Pollen is a Pregnancy Category C substance, meaning its safety has not been fully established in pregnant women. Most allergists recommend against starting a new course of allergy shots during pregnancy because of the risk of a severe allergic reaction, which could deprive the fetus of oxygen. However, if you are already on a stable maintenance dose and are tolerating it well, your doctor may allow you to continue the treatment. You should never increase your dose while pregnant. Always inform your allergist immediately if you discover you are pregnant.
Immunotherapy with Betula Occidentalis Pollen is a long-term commitment and does not provide instant relief. Most patients begin to notice an improvement in their allergy symptoms once they reach their 'maintenance dose,' which usually takes 3 to 6 months of weekly injections. Significant benefits are typically seen after the first full pollen season following the start of maintenance. For the best and most lasting results, the treatment must be continued for 3 to 5 years. This allows the immune system to fully develop a long-term tolerance to the pollen.
Yes, you can stop the treatment at any time without experiencing withdrawal symptoms, as it is not an addictive medication. However, stopping the treatment before the recommended 3-to-5-year course is finished usually means that your allergy symptoms will eventually return. The 'desensitization' effect requires consistent exposure to the extract over a long period to become permanent. If you need to stop due to side effects or life changes, discuss a plan with your doctor, as they may be able to adjust the dose instead of stopping entirely.
If you miss a scheduled allergy shot, contact your allergist's office as soon as possible to reschedule. Do not try to 'double up' on your next dose. If you miss only one week, you may be able to continue with your scheduled dose increase. However, if you miss several weeks, your doctor will likely need to reduce your dose for the next injection to ensure your safety and then gradually build it back up. Consistency is key to the success of immunotherapy, so try to stick to your schedule as closely as possible.
There is no scientific evidence to suggest that Betula Occidentalis Pollen extract causes weight gain. The extract consists of natural proteins and is administered in very small quantities that do not affect your metabolism or appetite. If you experience weight changes while on immunotherapy, they are likely due to other factors, such as lifestyle changes or other medications you may be taking (like oral steroids for asthma). If you have concerns about your weight, discuss them with your primary care physician.
Many common medications like antihistamines, nasal sprays, and asthma inhalers are safe and often necessary to take alongside Betula Occidentalis Pollen. However, certain medications like beta-blockers (used for heart conditions) and MAO inhibitors (used for depression) can make the treatment very dangerous because they interfere with the medications used to treat a severe allergic reaction. You must provide your allergist with a complete and updated list of every medication you take to ensure there are no dangerous interactions.
The concept of 'generic' vs. 'brand name' is different for allergenic extracts than for standard pills. Betula Occidentalis Pollen is a biological product produced by several different specialized laboratories (such as Greer, ALK, or HollisterStier). While the extracts from different companies are similar, they are not considered 'interchangeable' in the same way generic drugs are. If your doctor switches you to an extract from a different manufacturer, they will often restart the build-up phase or carefully adjust the dose to ensure safety.